Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$39.34 USD
-0.80 (-1.99%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $39.38 +0.04 (0.10%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SLNO 39.34 -0.80(-1.99%)
Will SLNO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLNO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLNO
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
SLNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
Other News for SLNO
Soleno Therapeutics Board Member to Step Down Peacefully
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)
Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)